Alternatively spliced androgen receptor variants.

Alternative splicing is an important mechanism for increasing functional diversity from a limited set of genes. Deregulation of this process is common in diverse pathologic conditions. The androgen receptor (AR) is a steroid receptor transcription factor with functions critical for normal male development as well as the growth and survival of normal and cancerous prostate tissue. Studies of AR function in androgen insensitivity syndrome (AIS) and prostate cancer (PCa) have demonstrated loss-of-function AR alterations in AIS and gain-of-function AR alterations in PCa. Over the past two decades, AR gene alterations have been identified in various individuals with AIS, which disrupt normal AR splicing patterns and yield dysfunctional AR protein variants. Recently, altered AR splicing patterns have been identified as a mechanism of PCa progression and resistance to androgen depletion therapy. Several studies have described the synthesis of alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the ultimate target of androgen depletion. Many of these truncated AR isoforms function as constitutively active, ligand-independent transcription factors that can support androgen-independent expression of AR target genes, as well as the androgen-independent growth of PCa cells. In this review, we will summarize the various alternatively spliced AR variants that have been discovered, with a focus on their role and origin in the pathologic conditions of AIS and PCa.

[1]  W. Isaacs,et al.  A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.

[2]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[3]  Majid I. Alsagabi,et al.  Molecular and Cellular Pathobiology Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression , 2011 .

[4]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[5]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[6]  S. Payton Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease , 2010, Nature Reviews Urology.

[7]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[8]  J. Céraline,et al.  Identification of novel truncated androgen receptor (AR) mutants including unreported pre‐mRNA splicing variants in the 22Rv1 hormone‐refractory prostate cancer (PCa) cell line , 2010, Human mutation.

[9]  H. Kung,et al.  ERK Regulates Calpain 2-induced Androgen Receptor Proteolysis in CWR22 Relapsed Prostate Tumor Cell Lines* , 2009, The Journal of Biological Chemistry.

[10]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[11]  H. Scher,et al.  Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.

[12]  D. Olmos,et al.  Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.

[13]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[14]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[15]  T. McDonald,et al.  Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-á-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2. , 2008, Endocrinology.

[16]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[17]  D. Toft,et al.  Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. , 2008, Molecular endocrinology.

[18]  I. Mills,et al.  Structural basis for the nuclear import of the human androgen receptor , 2008, Journal of Cell Science.

[19]  D. Tindall,et al.  Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. , 2007, Endocrine reviews.

[20]  D. Tindall,et al.  Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. , 2007, Cancer research.

[21]  C. Tepper,et al.  Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. , 2007, Cancer research.

[22]  J. Céraline,et al.  A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. , 2007, Endocrinology.

[23]  D. L. Bain,et al.  Nuclear receptor structure: implications for function. , 2007, Annual review of physiology.

[24]  G. Bartsch,et al.  Androgen axis in prostate cancer , 2006, Journal of cellular biochemistry.

[25]  N. Weigel,et al.  Androgen receptor action in hormone‐dependent and recurrent prostate cancer , 2006, Journal of cellular biochemistry.

[26]  D. Tindall,et al.  Molecular regulation of androgen action in prostate cancer , 2006, Journal of cellular biochemistry.

[27]  Kenneth J. Pienta,et al.  Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.

[28]  C. Sawyers,et al.  Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.

[29]  R. Fletterick,et al.  The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.

[30]  M. Menon,et al.  Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action , 2005, The Prostate.

[31]  C. Geserick,et al.  Androgen receptor function is modulated by the tissue‐specific AR45 variant , 2004, The FEBS journal.

[32]  Bin He,et al.  Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.

[33]  Hanne Grøn,et al.  Recognition and Accommodation at the Androgen Receptor Coactivator Binding Interface , 2004, PLoS biology.

[34]  Jian Hui Wu,et al.  The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.

[35]  F. Claessens,et al.  Structural basis of androgen receptor binding to selective androgen response elements. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Tepper,et al.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.

[37]  R. Dell’eva,et al.  The androgen receptor CAG repeat: a modifier of carcinogenesis? , 2002, Molecular and Cellular Endocrinology.

[38]  O. Hiort,et al.  The Molecular Basis of Androgen Insensitivity , 2001, Hormone Research in Paediatrics.

[39]  O. Hellwinkel,et al.  A unique exonic splicing mutation in the human androgen receptor gene indicates a physiologic relevance of regular androgen receptor transcript variants. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Rossi,et al.  Novel point mutation in the splice donor site of exon-intron junction 6 of the androgen receptor gene in a patient with partial androgen insensitivity syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[42]  M. A. Carrondo,et al.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. , 2000, The Journal of biological chemistry.

[43]  H. Gronemeyer,et al.  Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain* , 1999, The Journal of Biological Chemistry.

[44]  F. Claessens,et al.  The Androgen Receptor Amino-Terminal Domain Plays a Key Role in p160 Coactivator-Stimulated Gene Transcription , 1999, Molecular and Cellular Biology.

[45]  O. Hellwinkel,et al.  Complete androgen insensitivity caused by a splice donor site mutation in intron 2 of the human androgen receptor gene resulting in an exon 2-lacking transcript with premature stop-codon and reduced expression , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  J. Trapman,et al.  Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. , 1997, American journal of human genetics.

[47]  F. Ghadessy,et al.  A novel splice site mutation in the androgen receptor gene results in exon skipping and a non-functional truncated protein , 1997, Molecular and Cellular Endocrinology.

[48]  W. Pratt,et al.  Steroid receptor interactions with heat shock protein and immunophilin chaperones. , 1997, Endocrine reviews.

[49]  N. Chamberlain,et al.  Delineation of Two Distinct Type 1 Activation Functions in the Androgen Receptor Amino-terminal Domain* , 1996, The Journal of Biological Chemistry.

[50]  E. Wilson,et al.  A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. , 1994, The Journal of biological chemistry.

[51]  J. Trapman,et al.  Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. , 1994, American journal of human genetics.

[52]  J. Trapman,et al.  Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  F. S. French,et al.  Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[55]  D. Tindall,et al.  Selective Role of an NH 2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion – Independent Prostate Cancer Cells , 2007 .

[56]  F. Claessens,et al.  Interplay between two hormone-independent activation domains in the androgen receptor. , 2006, Cancer research.

[57]  M. Menon,et al.  Effect of a short CAG (glutamine) repeat on human androgen receptor function , 2004, The Prostate.

[58]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.